An assessment of prime-boost vaccination schedules with AS03A -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults

Paul Gillard, Adrian Caplanusi, Markus Knuf, François Roman, Karl Walravens, Philippe Moris, Mamadou Dramé, Tino F Schwarz, Paul Gillard, Adrian Caplanusi, Markus Knuf, François Roman, Karl Walravens, Philippe Moris, Mamadou Dramé, Tino F Schwarz

Abstract

Background: Long-term persistence of immune response and safety of an H5N1 prepandemic influenza vaccine adjuvanted with AS03 (an α-tocopherol oil-in-water emulsion-based adjuvant system) was evaluated using various prime-boost schedules that mimicked potential pandemic scenarios (NCT00430521).

Methods: Five hundred and twelve healthy adults aged 18-60 years received primary vaccination with one or two doses (0, 21 days schedule) of the A/Vietnam/1194/2004 H5N1 vaccine followed by a booster dose (A/Vietnam/1194/2004 or A/Indonesia/05/2005 strain) six or twelve months later across eight randomized groups. Immunogenicity results by hemagglutination inhibition [HI] assay, microneutralization assay, and the cell-mediated immune response (CMI) are reported here for the four groups boosted at Month 12.

Results: A one-dose-adjuvanted primary administration followed 12 months later by a single-adjuvanted booster dose containing a heterologous vaccine strain met or exceeded all US and European criteria for both strains. Increasing the interval between the first and second dose (from 21 days to 12 months) resulted in stronger cross-reactive immune responses against the A/Indonesia/05/2005 strain. The HI antibody response against the two strains persisted for 6 months after the booster dose irrespective of the booster vaccine's strain. The neutralizing antibody responses and the CMI observed in the study population paralleled the HI immune response. Overall, the vaccine had a clinically acceptable safety profile.

Conclusion: The H5N1 vaccine in this study allowed for flexibility in the time interval between primary and booster vaccination and the use of a heterologous strain without impacting the strength of the humoral and cellular immune response to both vaccine strains.

© 2012 Blackwell Publishing Ltd.

Figures

Figure 1
Figure 1
Study design diagram + CONSORT. Explanation for the study design: In the primary study, subjects were randomized into 8 study groups to receive one or two doses (21 days apart) of AS03A‐adjuvanted H5N1 vaccine with either A/Vietnam/1194/2004 strain (VT) or A/Indonesia/05/2005 strain (IN). A homologous or heterologous booster dose (VT or IN) was administered to 4 study groups at Month 6 and the remaining 4 study groups at Month 12. Blood samples were drawn before vaccination, at Days 21 and 42, Month 6 (+7 and +30 days), Month 12 (+7 and +21 days), and at Month 18. This manuscript presents data from groups that were boosted at Month 12. Group names: VT/VT/M12: A/Vietnam/1194/2004 vaccine at Day 0; A/Vietnam/1194/2004 vaccine at Month 12. VT/IN/M12: A/Vietnam/1194/2004 vaccine at Day 0; A/Indonesia/05/2005 vaccine at Month 12. 2VT/VT/M12: A/Vietnam/1194/2004 vaccine at Days 0 and 21; A/Vietnam/1194/2004 vaccine at Month 12. 2VT/IN/M12: A/Vietnam/1194/2004 vaccine at Days 0 and 21; A/Indonesia/05/2005 vaccine at Month 12.
Figure 2
Figure 2
(A) Reverse cumulative curves for HI antibody response against the A/Vietnam/1194/2004 and A/Indonesia/05/2005 strains at all time points (per‐protocol cohort for immunogenicity). (B) Reverse cumulative curves for neutralizing antibody response against the A/Vietnam/1194/2004 and A/Indonesia/05/2005 strains at all time points (per‐protocol cohort for immunogenicity). For group names see Figure 1.
Figure 3
Figure 3
(A, B) Cell‐mediated immune response at Months 12 and 18 (per‐protocol cohort for immunogenicity). For group names see Figure 1.
Figure 4
Figure 4
(A, B) Split H5N1‐specific memory B cell response against the A/Vietnam/1194/2004 and A/Indonesia/05/2005 strains at all time points (per‐protocol cohort for immunogenicity). For group names see Figure 1.
Figure 5
Figure 5
(A) Solicited local symptoms reported during the 7‐day post‐vaccination follow‐up period after Month 12 booster (total vaccinated cohort). (B) Solicited general symptoms reported during the 7‐day post‐vaccination follow‐up period after Month 12 booster (total vaccinated cohort). Error bars indicate the upper and lower limits of the 95% confidence intervals (CIs). For group names see Figure 1.

References

    1. Melidou A, Gioula G, Exindari M, Chatzidimitriou D, Diza‐Mataftsi E. Influenza A (H5N1): an overview of the current situation. Eurosurveillance 2009; 145:220–226.
    1. World Health Organization (WHO) . Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO, 6 May 2010. Global alert and response (GAR) Available at (Accessed 26 July 2011).
    1. World Health Organization (WHO) . Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses for the development of candidate vaccine viruses for pandemic preparedness, February 2011. Available at (Accessed 23 May 2011).
    1. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus . Update on Avian Influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261–273.
    1. European Committee for Proprietary Medicinal Products (CHMP) . Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/2006). European Agency for the Evaluation of Medicinal Products, January 24, 2007.
    1. US Food and Drug Administration (FDA) Guidance for Industry . Clinical data needed to support the licensure of pandemic influenza vaccines. US Food and Drug Administration May 2007. Available at (Accessed 10 March 2011).
    1. World Health Organization (WHO) . Options for the Use of Human H5N1 Influenza Vaccines and the WHO H5N1 Vaccine Stockpile. Geneva, Switzerland: WHO scientific consultation, 2007.
    1. Stephenson I, Gust I, Pervikov Y, Kieny MP. Development of vaccines against influenza H5. Lancet Infect Dis 2006; 6:458–460.
    1. World Health Organization . Pandemic (H1N1) 2009 briefing note 2. Global alert and response (GAR) July 13, 2009. Available at (Accessed 16 March 2011).
    1. Chu DW‐S, Hwang SJ, Lim FS et al. Immunogenicity and tolerability of an AS03A‐adjuvanted prepandemic influenza vaccine. A phase III study in a large population of Asian adults. Vaccine 2009; 27:7428–7435.
    1. Leroux‐Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross‐reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580–589.
    1. Leroux‐Roels I, Bernhard R, Gerard P, Dramé M, Hanon E, Leroux‐Roels G. Broad clade 2 cross‐reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 2008; 3:e1665 499. Doi: .
    1. Rümke HC, Bayas JM, de Juanes JR et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008; 26:2378–2388.
    1. Schwarz TF, Horacek T, Knuf M et al. Single dose vaccination with AS03‐adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27:6284–6290.
    1. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti‐H5 responses in human sera by HI using horse erythrocytes following MF59‐adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004; 103:91–95.
    1. Reed LT, Muench H. A simple method of calculating fifty percent end point. Am J Hyg 1938; 27:493–498.
    1. Moris P, van der Most R, Leroux‐roels I et al. H5N1 influenza vaccine formulated with AS03A induces strong cross‐reactive and polyfunctional CD4 T‐cell responses. J Clin Immunol 2011; 31:443–454.
    1. Malherbe L, Mark L, Fazilleau N, Heyzer‐Williams LJ, Heyzer‐Williams MG. Vaccine adjuvants alter TCR‐based selection thresholds. Immunity 2008; 28:698–709.
    1. Khurana S, Verma N, Yewdell JW et al. MF59 adjuvant enhances diversity and affinity of antibody‐mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011; 3:85ra48.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit